COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01562834
Recruitment Status : Completed
First Posted : March 26, 2012
Last Update Posted : February 27, 2017
Sponsor:
Information provided by (Responsible Party):
Novo Nordisk A/S

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This trial is conducted in Europe. The aim of this trial is to assess the effect of somatropin (Norditropin®) replacement therapy on the left ventricular mass of adult patients with a growth hormone deficiency.

Condition or disease Intervention/treatment Phase
Growth Hormone Disorder Adult Growth Hormone Deficiency Drug: somatropin Drug: placebo Phase 4

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 22 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Randomized Cross Over Double Blind Versus Placebo Trial Followed by an Open Phase Studying Effect of Norditropin® on Left Ventricular Mass of Growth Hormone Deficient Adult Patients
Actual Study Start Date : October 21, 1998
Actual Primary Completion Date : December 1, 2002
Actual Study Completion Date : December 1, 2002

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hormones

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Somatropin Drug: somatropin
Initial dosage 0.5 IU/day, injected subcutaneously (s.c., under the skin) once daily. Dosage will be adjusted monthly depending on clinical safety up to a maximum dose of 3 IU/day. Subjects are treated for six months (randomised trial period) followed by an 12-month open-label trial period with somatropin.
Placebo Comparator: Placebo Drug: placebo
Initial dosage 0.5 IU/day, injected subcutaneously (s.c., under the skin) once daily. Dosage will be adjusted monthly depending on clinical safety up to a maximum dose of 3 IU/day. Subjects are treated for six months. After treatment in the randomised trial period, placebo will be discontinued.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Left ventricular mass measured with ultrasonography

Secondary Outcome Measures :
  1. Ventricular function indices assessed by cardiac ultrasonography
  2. Bone mineral density and body composition assessed by DEXA (Dual Energy X-Ray Absorptiometry)
  3. Quality of life using EQ5D (European Quality of Life 5 Dimensions) scales
  4. IGF-I (Insulin-Like Growth Factor I) concentration

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Childhood or adult onset growth hormone deficiency (GHD)
  • GHD evidenced by two stimulation tests
  • Duration of GHD at least 5 years
  • Other hormone deficiencies associated with growth hormone deficiency

Exclusion Criteria:

  • Pregnancy or pregnancy desired during the suggested duration of the study
  • Personal history of colonic polyp or family history of colonic polyposis
  • Known insulin-dependent or non-insulin-dependent diabetes
  • Cardiovascular disease, left ventricular hypertrophy from other aetiology, recent auricular or ventricular arrhythmia, history of vascularisation by aortocoronary bypass significative mitral or aortic valvular disease, preexcitation syndrome, auriculoventricular conduction delay, bradycardia-tachycardia syndrome, left ventricular mass interfering treatment
  • BMI (Body Mass Index) at least 30
  • Growth hormone treatment during the 24 months prior to inclusion, history of treatment with extractive pituitary growth hormone, allergy or suspected allergy to somatropin therapy
  • Patient who has participated in a different clinical study within the past two months
  • Any condition which, in the opinion of the Investigator or the Scientific Committee, may interfere with successful implementation of the study
  • Notion of breast cancer for the mother or the sister
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01562834


Locations
Layout table for location information
France
Novo Nordisk Investigational Site
ANGERS cedex 09, France, 49033
Novo Nordisk Investigational Site
Boisguillaume, France, 76233
Novo Nordisk Investigational Site
Brest, France, 29609
Novo Nordisk Investigational Site
Caen, France, 14033
Novo Nordisk Investigational Site
Grenoble, France, 38043
Novo Nordisk Investigational Site
Le Kremlin-bicetre, France, 94275
Novo Nordisk Investigational Site
Lille, France, 59037
Novo Nordisk Investigational Site
Lorient, France, 56322
Novo Nordisk Investigational Site
Lyon, France, 69394
Novo Nordisk Investigational Site
Lyon, France, 69437
Novo Nordisk Investigational Site
MARSEILLE Cédex 05, France, 13385
Novo Nordisk Investigational Site
MONTPELLIER cedex 5, France, 34295
Novo Nordisk Investigational Site
Nantes, France, 44000
Novo Nordisk Investigational Site
Nantes, France, 44093
Novo Nordisk Investigational Site
Nice, France, 06002
Novo Nordisk Investigational Site
Paris, France, 75010
Novo Nordisk Investigational Site
Paris, France, 75015
Novo Nordisk Investigational Site
Paris, France, 75571
Novo Nordisk Investigational Site
Reims, France, 51092
Novo Nordisk Investigational Site
Rennes, France, 35056
Novo Nordisk Investigational Site
Strasbourg, France, 67098
Novo Nordisk Investigational Site
TOULOUSE cedex, France, 31054
Novo Nordisk Investigational Site
Tours, France, 37044
Novo Nordisk Investigational Site
Vandoeuvre Les Nancy, France, 54511
Sponsors and Collaborators
Novo Nordisk A/S
Investigators
Layout table for investigator information
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Layout table for additonal information
Responsible Party: Novo Nordisk A/S
ClinicalTrials.gov Identifier: NCT01562834    
Other Study ID Numbers: GHDADULT/F/1/F
First Posted: March 26, 2012    Key Record Dates
Last Update Posted: February 27, 2017
Last Verified: February 2017